San Antonio Independent School District v. Rodriguez: A Retreat from Equal Protection

With these words, the Supreme Court in Brown v. Board of Education, unanimously declared that the long-standing, state- enforced doctrine of separate but equal denied equal protection of the laws to non-white pupils in state-supported schools. Recognizing the fundamental importance of an education in modern society and finding that [s]eparate education facilities are inherently unequal, the Court ruled that a state could no longer make the extent of a child\u27s educational opportunity a function of the color of his skin. Nineteen years later, the Supreme Court was called upon in San Antonio Independent School District v.Rodriguezs to review the constitutionality of another long-standing, state-enforced practice of affecting education. This time the challenge was to the Texas scheme of financing public elementary and secondary education. This scheme, and those in nearly every state, relied primarily upon local ad valorem property taxes, and resulted in great disparities between school districts in the amount of funds available for educational expenditures

The Lantern Vol. 31, No. 2, May 1964

• The High, Forbidding Wall • Sonnet One • Sceptic • The Witch, the Prince, and the Princess • Portrait in Gold and Black • The Music of the Drum • Sweat It, Jack • Cold Blue and the Moon • Another Carpenter: Circa 1963 • At a Conference of Colonial Historians • Pineland Places • Diasia to Death • Hey!... • The Hour • I\u27ll Not Returnhttps://digitalcommons.ursinus.edu/lantern/1086/thumbnail.jp

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation